IPI Legacy Liquidation Co
IPI Legacy Liquidation Co (IMPL): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.9 months
D/E -1.38 · 0% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for IPI Legacy Liquidation Coacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$4.7M
Quarterly Burn
$16.5M
Runway
1.9 mo
Revenue
$5.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| trudhesa | Approved |
Frequently asked questions
How many drug candidates are in IPI Legacy Liquidation Co's pipeline?
IPI Legacy Liquidation Co (IMPL) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is IPI Legacy Liquidation Co's lead drug candidate?
IPI Legacy Liquidation Co's most advanced tracked candidate is trudhesa (Approved) for acute treatment of migraine headaches with or without aura in adults.
What is IPI Legacy Liquidation Co's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IPI Legacy Liquidation Co has approximately 1.9 months of cash runway.
Who is the CEO of IPI Legacy Liquidation Co?
Washington April is the chief executive officer of IPI Legacy Liquidation Co (IMPL).
Get the full picture on IPI Legacy Liquidation Co
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.